Home

CARB-X accelerates global antibacterial innovation by supporting the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our portfolio represents the world’s most scientifically diverse, early development pipeline of new antibiotics, vaccines, rapid diagnostics, and other products to prevent, diagnose and treat life-threatening bacterial infections.

490

$million

Invested

104

innovative

Projects

13

different

Countries

12

human clinical

TRIALS

2

available

DIAGNOSTICS

2

advanced development

FUNDING

The Challenge

Accelerate the development of novel antibiotics and other new approaches to address drug-resistant bacterial infections.
Learn More


2023

Annual Report

Accelerating the Global Response to Antimicrobial Resistance

Learn More

“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”

— Tim Jinks, Head of Infectious Diseases Interventions, Wellcome. Watch this video on what CARB-X is doing to address the rise of drug-resistant bacteria.

GHTC logo and Innovation award noticeProud recipient of the

2020 Innovating for Impact Partnership Award

from the Global Health Technologies Coalition (GHTC) 

Watch video

 

 

Funders

ASPR
BARDA
Wellcome
NIAID
UK Government
Bill & Melinda Gates Foundation
The Public Health Agency of Canada
Novo Nordisk Foundation

Events

Events

02.04.25

 

Antimicrobial Chemotherapy Conference

02.25.25

 

9th AMR Conference

CARB-X News

  • 11.26.2024  |  CARB-X and CHAI partner to sharpen AMR response, tackle gonorrhea in low- and middle-income countries full release

  • 11.07.2024  |  CARB-X applauds G20 Health Ministers’ commitments to control antimicrobial resistance full release

  • 10.31.2024  |  CARB-X appoints Andy Soares White as Chief Financial Officer full release

See All News

In The News

  • 12.02.2024  |  CARB-X to partner with Clinton Health Access Initiative on gonorrhea-focused interventions full story

  • 11.26.2024  |  CARB-X and CHAI partner to sharpen AMR response, tackle gonorrhea in low- and middle-income countries full story

  • 11.26.2024  |  Fighting back against antimicrobial resistance: Partnerships and innovations full story

See All News

Sign up for CARB-X news

Get the latest news and announcements from CARB-X.

Subscribe

* indicates required